ZeptoMetrix (ZMC) has its roots in a number of places. The original company was
a Buffalo based biotechnology business named Cellular Products, Inc. (CPI). CPI
began as an offshoot of the National Cancer Institute and its first product was
T Cell Growth Factor, a product that ZMC still sells today.

CPI accomplished some major scientific feats. CPI was one of the first to launch a
blood screening test for HIV and was the first to develop tests for Human T Cell
Leukemia Virus and HIV p24 Antigen. However, CPI was a financially troubled
company, in a large part because of its decision to compete with industry giants.

CPI continued to be financially troubled, was bought and sold a couple of times and even went through a chapter 11 bankruptcy. In the mid 90's Dr. Jim Hengst came to Buffalo, became head of CPI, and restructured the company to focus on its research products market. In 1999, Jim, together with Chris Collins, now our chairman, bought CPI from Hemagen Diagnostics and renamed the organization, ZeptoMetrix.

Although still financially troubled, ZMC aggressively pursued its research products focus and it's restructuring. The company successfully competed for and received $1.6 million in grants from the National Cancer Institute and National Heart, Lung and Blood Institute. In 2000, ZeptoMetrix launched over 20 new products and by 2001 the company was solidly profitable.

ZMC continued its organic growth by developing and launching more products and by taking on contract work for other biotechnology companies. Eventually ZMC had the cash to begin pursuing technology development programs. Technology development programs aim at creating new technologies that at a later time can be further developed into products.

A major success from ZMC's technology development programs was NATtrol. This was developed jointly with Dr. Greg Chiklis who headed R&D for Impath's BCP division. ZMC and Impath entered into a joint agreement to create and sell a comprehensive line of NATtrol prducts, something that gave Impath's BCP division products that were far superior to anything offered by their competitors. Impath, at the time, had poured millions into BCP's facilities, equipment and infrastructure.

In 2003, Impath, a public company, hit major financial problems following the announcement that they had misstated their financials. Impath was assaulted by numerous class action law suits, a number of their executives were brought up on charges by the SEC, and Impath was forced to file chapter 11 and liquidate.

As a result of this, in April 2004, ZMC acquired the BCP division from Impath and also complete ownership of the NATtrol technology.

The marriage of ZMC and BCP was an immediate success. The complementarity of the two company's businesses, products and customers could not have been better. Even the culture of the two companies was matched as perfectly as identical twins. Both companies have highly trained professionals who are not only deadly serious about their work, but are also fun loving people who really enjoy the work they are doing. The ZMC staff represents some of the best in the biotechnology industry.